Stock highlight: Cephalon (CEPH--57.15)

Article Abstract:

The stock market standing of Cephalon, a biopharmaceutical company based in Pennsylvania with regard to the tentative sales of all its products provided with Food and Drugs Administration (FDA) approval is analyzed. Analysis shows that 2003 share earnings represented a record high for the company with same expectations for 2004 but investment risks do not warrant holding these shares on long term basis due to Cephalon's FDA leanings.

United States, Sales, profits & dividends, Forecasts, trends, outlooks, Commodity & service prices, Prices and rates, Forecasts and trends, Market trend/market analysis, Company sales and earnings, Company earnings/profit, Powers and duties, United States. Food and Drug Administration, Company pricing policy

---

Cephalon, Inc

Article Abstract:

The shares of Cephalon Inc. have above-average price appreciation potential over the 2010-2012 timeframe. The Frazer, Pennsylvania-based company offers products used for the treatment of neurological and sleep disorders, cancer, and pain.

---

Cephalon, Inc

Article Abstract:

The shares of Cephalon Inc. have an average price appreciation potential over the 2010-2012 timeframe. The Frazer, Pennsylvania-based company develops and markets products to treat neurological and sleep disorders, cancer, and pain.

Analyst report

Similar abstracts:

• Abstracts: PepsiAmericas Inc. Stock highlight: PepsiAmericas (PAS-21.24)
• Abstracts: DeVry Inc. Stock highlight: DeVry Inc
• Abstracts: PETsMART, Inc.. Stock highlight: PETSMART (PETM - 31.18)
• Abstracts: Machinery industry: Saufer-Danfoss Inc.: NYSE-SHS. Park Electrochemical Corporation
• Abstracts: Securities Brokerage Industry: Legg Mason, Inc.: NYSE-LM. Securities Brokerage Industry: Charles Schwab Corporation: NYSE-SCH

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.